Abstract Number: 944 • 2013 ACR/ARHP Annual Meeting
Mir-125a: A Novel Regulator Of IL-6 and TLR Driven Pathways In RA Pathogenesis
Background/Purpose: Molecular mechanisms driving disease initiation and chronicity in RA are incompletely understood. There is increasing interest in the role played therein by microRNAs –…Abstract Number: 2573 • 2013 ACR/ARHP Annual Meeting
The Role Of STAT-3 In The Development Of Pulmonary and Dermal Fibrosis
Background/Purpose: Fibrosis is the accumulation of excessive extra-cellular matrix in tissues, leading to tissue damage. In systemic sclerosis, the trigger is postulated to be an…Abstract Number: 1766 • 2013 ACR/ARHP Annual Meeting
Role Of IL33 In The Inflammation Of Takayasu Arteritis
Background/Purpose: Interleukin (IL)-33, a member of the IL-1 cytokine family, is a recently described novel activator of endothelial cells, which promotes adhesion molecules and proinflammatory…Abstract Number: 881 • 2013 ACR/ARHP Annual Meeting
Time To Renal Flare and Renal Disease Activity Over a 1 Year Period Is associated With Urinary TWEAK Levels In Patients With Systemic Lupus Erythematosus
Background/Purpose: TNF-like weak inducer of apoptosis (TWEAK) is a member of the TNF superfamily that signals through its distinct, highly inducible receptor, FGF-inducible molecule 14…Abstract Number: 2537 • 2013 ACR/ARHP Annual Meeting
Inactive Systemic Lupus Erythematosus: Cytokines and Soluble Tumor Necrosis Factor Receptors Response To Moderate/Intense Exercise
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease characterized by a chronic inflammation associated with worse cardiovascular outcome. Although a few studies have…Abstract Number: 1767 • 2013 ACR/ARHP Annual Meeting
Gender, Race, and Soluble Mediators Distinguish Blood Relatives Who Develop Incomplete Lupus Or Classified SLE In The Lupus Autoimmunity In Relatives (LAUREL) Study
Background/Purpose: Identifying populations at risk of SLE is essential to curtail inflammatory damage and identify individuals for prevention trials. Healthy blood relatives (FDRs) of lupus…Abstract Number: 842 • 2013 ACR/ARHP Annual Meeting
A Cytokine/Chemokine Multiplex Assay That Is Sensitive and Specific For Fibromyalgia Compared To Controls, Systemic Lupus Erythematosus, and Rheumatoid Arthritis
Background/Purpose: Fibromyalgia (FM) is a chronic pain and fatigue syndrome that affects about 6 million adults in the United States. The clinical diagnosis of…Abstract Number: 2545 • 2013 ACR/ARHP Annual Meeting
Active Systemic Lupus Erythematosus: Cytokines and Soluble Tumor Necrosis Factor Receptors Response To Moderate/Intense Exercise
Background/Purpose: Systemic lupus erythematosus (SLE) is a rheumatic autoimmune condition characterized by altered lipoprotein profile, physical dysfunction and increased risk of cardiovascular disease. Exercise is,…Abstract Number: 1685 • 2013 ACR/ARHP Annual Meeting
Long-Term Use Of Tocilizumab For The Treatment Of Giant Cell Arteritis
Background/Purpose: A sizeable percentage of giant cell arteritis (GCA) patients experience disease relapse upon glucocorticoid (GC) tapering, and a clearly effective GC-sparing alternative has not…Abstract Number: 643 • 2013 ACR/ARHP Annual Meeting
Potential Immunopathological Roles Of The Novel Anti-Inflammatory Cytokine Interleukin-35 In Patients With Systemic Lupus Erythematous
Background/Purpose: IL-35, a dimeric protein with two subunits, IL-12A (p35) and Epstein-Barr virus induced 3, is a novel IL-12 cytokine family regulatory T-cells (Treg)-specific immunosuppressive/anti-inflammatory…Abstract Number: 2499 • 2013 ACR/ARHP Annual Meeting
Analysis Of Inflammatory Markers Within Facet Joints Of Patients Within Ankylosing Spondylitis
Background/Purpose: Inflammation within sacroiliac joints and within the spine is a hallmark of ankylosing spondylitis (AS). Apart from nonsteroidal anti-rheumatic drug (NSAID) treatment, inhibition of…Abstract Number: 1691 • 2013 ACR/ARHP Annual Meeting
The STAT1 Signaling Pathway In Giant Cell Arteritis
Background/Purpose: In giant cell arteritis (GCA), CD4 T cells, macrophages and multinucleated giant cells form granulomatous lesions in the walls of medium and large arteries.…Abstract Number: 635 • 2013 ACR/ARHP Annual Meeting
Multiple Altered Soluble Inflammatory Mediators Correlate With Disease Activity and Mark Impending Disease Flare In European-American Lupus Patients
Background/Purpose: SLE is a waxing and waning disease characterized by immune dysregulation, major organ involvement, and disease flares. Identifying mechanistic mediators of altered disease activity…Abstract Number: 2423 • 2013 ACR/ARHP Annual Meeting
Mir-27b As Biomarker and Regulator Of IL-6R Pathway In Resistant Rheumatoid Arthritis Monocyte
Background/Purpose: Whereas molecular mechanisms mediating treatment responses to biologic DMARDS in Rheumatoid Arthritis (RA) are emerging, those pathways that subserve treatment resistance are poorly explored.…Abstract Number: 1683 • 2013 ACR/ARHP Annual Meeting
High Prevalence Of Metabolic Syndrome In Takayasu Arteritis: An Increased Cardiovascular Risk and Lower Adiponectin Serum Levels
Background/Purpose: The prevalence of Metabolic Syndrome (MetS) tends to be high among rheumatic patients, and cardiovascular disease is the leading cause of death in these…
- « Previous Page
- 1
- …
- 30
- 31
- 32
- 33
- 34
- …
- 38
- Next Page »